WO1986003751A3 - Purification, production et utilisation de facteurs necrotiques tumoraux - Google Patents

Purification, production et utilisation de facteurs necrotiques tumoraux

Info

Publication number
WO1986003751A3
WO1986003751A3 PCT/EP1985/000721 EP8500721W WO8603751A3 WO 1986003751 A3 WO1986003751 A3 WO 1986003751A3 EP 8500721 W EP8500721 W EP 8500721W WO 8603751 A3 WO8603751 A3 WO 8603751A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
polypeptides
tumor necrosis
necrosis factors
tnfs
Prior art date
Application number
PCT/EP1985/000721
Other languages
English (en)
Other versions
WO1986003751A2 (fr
Inventor
Walter C Fiers
Lucia M Fransen
Jan Honore Leo Tavernier
Anne Louis Marie Marmenout
Der Heyden Jose Van
Bernard Allet
Eric H Kawashima
Original Assignee
Biogen Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Nv filed Critical Biogen Nv
Priority to JP61500550A priority Critical patent/JP2557053B2/ja
Priority to DE8686900138T priority patent/DE3585690D1/de
Priority to AT86900138T priority patent/ATE73856T1/de
Publication of WO1986003751A2 publication Critical patent/WO1986003751A2/fr
Publication of WO1986003751A3 publication Critical patent/WO1986003751A3/fr
Priority to DK399786A priority patent/DK399786D0/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Procédé de production de facteurs nécrotiques tumoraux (TNF) de mammifères et polypeptides similaires aux TNF, par culture d'hôtes procaryotiques transformés avec une molécule d'ADN recombinant comprenant des séquences d'ADN codant ces polypeptides liés de manière opérationnelle à l'une ou l'autre des séquences de commande d'expression T4 ou pL-T4. Procédé de purification de polypeptides similaires aux TNF par l'utilisation d'un échangeur d'anions. Les TNF et les polypeptides similaires aux TNF produits par ces procédés, ainsi que les compositions et les procédés les utilisant, sont utiles dans les thérapies contre les cancers, les tumeurs et le paludisme. Ces composés sont utiles également en combinaison avec une chimiothérapie et une thérapie à l'interféron dans la lutte contre les cancers et les tumeurs, et en combinaison avec l'actinomycine D dans le traitement de mammifères affectés par des tumeurs.
PCT/EP1985/000721 1984-12-21 1985-12-19 Purification, production et utilisation de facteurs necrotiques tumoraux WO1986003751A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP61500550A JP2557053B2 (ja) 1984-12-21 1985-12-19 腫瘍壊死因子の精製、製造および使用法
DE8686900138T DE3585690D1 (de) 1984-12-21 1985-12-19 Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren.
AT86900138T ATE73856T1 (de) 1984-12-21 1985-12-19 Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
DK399786A DK399786D0 (da) 1984-12-21 1986-08-21 Rensning, fremstilling og anvendelse af tumornekrosefaktorer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68459584A 1984-12-21 1984-12-21
US684,595 1984-12-21
US785,847 1985-10-05
US78584785A 1985-10-09 1985-10-09

Publications (2)

Publication Number Publication Date
WO1986003751A2 WO1986003751A2 (fr) 1986-07-03
WO1986003751A3 true WO1986003751A3 (fr) 1986-08-14

Family

ID=27103367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1985/000721 WO1986003751A2 (fr) 1984-12-21 1985-12-19 Purification, production et utilisation de facteurs necrotiques tumoraux

Country Status (16)

Country Link
US (1) US5487984A (fr)
EP (3) EP0216786B1 (fr)
JP (4) JP2557053B2 (fr)
KR (1) KR940010865B1 (fr)
AT (1) ATE73856T1 (fr)
AU (2) AU601675B2 (fr)
DE (1) DE3585690D1 (fr)
DK (1) DK399786D0 (fr)
ES (1) ES8705521A1 (fr)
FI (1) FI86194C (fr)
HU (1) HUT40702A (fr)
IE (1) IE58709B1 (fr)
NO (1) NO855216L (fr)
NZ (1) NZ214711A (fr)
PT (1) PT81754B (fr)
WO (1) WO1986003751A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US5081021A (en) * 1986-02-04 1992-01-14 Mizuno Den Ichi DNA encoding HTNF variants exhibiting enhanced activity
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
CA2067821A1 (fr) * 1989-10-24 1991-04-25 Cetus Oncology Corporation Mecanisme infectieux d'administration d'un medicament faisant appel a des vecteurs retroviraux recombinants
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
ES2184756T3 (es) * 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
AU3818095A (en) * 1994-10-20 1996-05-15 Industrial Research Limited Separation of amino acids and peptides from protein hydrolysates
AU761216B2 (en) * 1996-03-14 2003-05-29 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU2003236393B2 (en) * 1996-03-14 2006-02-02 Human Genome Sciences, Inc. Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis
US7217788B2 (en) * 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6509170B1 (en) 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
CA2247285C (fr) * 1996-03-14 2011-11-08 Human Genome Sciences, Inc. Facteurs de necrose tumorale delta et epsilon chez l'homme
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
EP1401870A4 (fr) * 2001-05-24 2006-04-19 Human Genome Sciences Anticorps contre le facteur de necrose tumorale delta (april)
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
CA2508375C (fr) * 2002-12-02 2014-05-27 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
JP2005132795A (ja) * 2003-10-31 2005-05-26 Genichiro Soma 抗悪性神経膠腫剤及び動物用抗悪性神経膠腫剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US11111284B2 (en) * 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
WO2016187068A1 (fr) 2015-05-15 2016-11-24 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose anti-tumoral
EP3355914B1 (fr) 2015-09-29 2024-03-06 The General Hospital Corporation Une composition comprenant bcg pour réduire le cholesterol.
WO2017197331A2 (fr) 2016-05-13 2017-11-16 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose contre les tumeurs
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3227262A1 (de) * 1981-07-21 1983-03-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Verfahren zur herstellung von target-zellen-lysis-faktor und dessen verwendung
EP0131789A2 (fr) * 1983-06-27 1985-01-23 Sloan-Kettering Institute For Cancer Research Composition contenant le facteur de nécrose de tumeurs purifié en association avec l'interféron humain et son application
EP0146026A2 (fr) * 1983-12-02 1985-06-26 Dainippon Pharmaceutical Co., Ltd. ADN codant pour TNF de lapin, vecteur dans lequel cet ADN est inséré, hôte transformé par ce vecteur, polypeptide TNF de lapin et procédé pour sa préparation
EP0148311A1 (fr) * 1983-12-26 1985-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Un polypeptide nouveau physiologiquement actif
EP0170843A1 (fr) * 1984-06-23 1986-02-12 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mélanges synergiques d'interférons et d'un facteur provoquant la nécrose de tumeurs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
NL7903195A (nl) 1979-04-24 1980-10-28 Philips Nv Inrichting voor kunstmatige nagalm.
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0041767B1 (fr) 1980-06-06 1993-03-03 Biogen, Inc. Vecteurs améliorés, méthodes de construction de tels vecteurs et d'expression de gènes clonés
WO1984001288A1 (fr) * 1982-10-06 1984-04-12 Takeshi Makitsubo Procede d'extraction du facteur de necrose de tumeur a partir d'un macrophage
EP0155549B1 (fr) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. ADN codant pour le facteur humain de nécrose de tumeur et le polypeptide du facteur humain de nécrose de tumeur
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
GR851626B (fr) * 1984-07-05 1985-11-26 Genentech Inc
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4677663A (en) * 1985-07-05 1987-06-30 Melita Electronic Labs, Inc. Telephone answering and call forwarding improvement
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3227262A1 (de) * 1981-07-21 1983-03-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Verfahren zur herstellung von target-zellen-lysis-faktor und dessen verwendung
EP0131789A2 (fr) * 1983-06-27 1985-01-23 Sloan-Kettering Institute For Cancer Research Composition contenant le facteur de nécrose de tumeurs purifié en association avec l'interféron humain et son application
EP0146026A2 (fr) * 1983-12-02 1985-06-26 Dainippon Pharmaceutical Co., Ltd. ADN codant pour TNF de lapin, vecteur dans lequel cet ADN est inséré, hôte transformé par ce vecteur, polypeptide TNF de lapin et procédé pour sa préparation
EP0148311A1 (fr) * 1983-12-26 1985-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Un polypeptide nouveau physiologiquement actif
EP0170843A1 (fr) * 1984-06-23 1986-02-12 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mélanges synergiques d'interférons et d'un facteur provoquant la nécrose de tumeurs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Gene, Volume 18, No. 3, June 1982, N. CASNA et al.: "Bacteriophage T4 as a Generalized DNA-Cloning Vehicle", pages 297-307, see page 306 *
Infection and Immunity, Volume 28, No. 1, April 1980, Washington, DC, (US) D.N. MANNEL et al.: "Generation and Characterization of al Lipopolysaccharide-Induced and Serum-Derived Cytotoxic Factor for Tumor Cells", see pages 204-211, page 209, left-hand column, lines 9-15; figure 7 *
Infection and Immunity, Volume 30, No. 2, November 1980, Washington, D.C., (US) D.N. MANNEL et al.: "Macrophages as a Source of Tumoricidal Activity (Tumor Necrotizing Factor)", see pages 523-530, page 527, left-hand column, lines 22-35; page 528; figure 4 (cited in the application) *
Infection and Immunity, Volume 31, No. 1, January 1981, Washington, D.C., (US) M.R. RUFF et al.: "Rabbit Tumor Necrosis Factor: Mechanism of Action", see pages 380-385, see page 381, right-hand column, lines 7-12 (cited in the appliction) *
Nature, Volume 312, No. 5996, December - January 1984/1985, London (GB) D. PENNICA et al.: Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin", pages 724-729, see the whole document *
Nature, Volume 312, No. 59968 December-January 1984/1985, London (GB) K. SIKORA: "Cancer Toxin Genes Cloned", pages 699-700, see the whole document *
Proceedings of the National Academy of Sciences (USA), Volume 79, August 1982 H.M. Krisch et al.: Nucleotide Sequences Involved in Bacteriophage T4 Gene 32 Translational Self-Regulation", pages 4937-4941, see the whole document *
See also references of EP0216786A1 *
The Journal of Immunology, Volume 125, No. 4, October 1980, Baltimore, MD, (US) M.R. RUFF et al: "Purification and Physicochemical Characterization of Rabbit Tumor Necrosis Factor", see pages 1671-1677, page 1673, left-hand column, lines 47-53 *

Also Published As

Publication number Publication date
AU5301486A (en) 1986-07-22
KR860005023A (ko) 1986-07-16
WO1986003751A2 (fr) 1986-07-03
HUT40702A (en) 1987-01-28
JPH07213293A (ja) 1995-08-15
EP0216786A1 (fr) 1987-04-08
ES8705521A1 (es) 1987-05-01
JP2548527B2 (ja) 1996-10-30
FI855130A0 (fi) 1985-12-20
JPH07213291A (ja) 1995-08-15
EP0313104A3 (fr) 1989-07-12
IE853273L (en) 1986-06-21
JPS62501470A (ja) 1987-06-18
JP2557053B2 (ja) 1996-11-27
DK399786A (da) 1986-08-21
NO855216L (no) 1986-06-23
AU601675B2 (en) 1990-09-20
US5487984A (en) 1996-01-30
JP2548525B2 (ja) 1996-10-30
ATE73856T1 (de) 1992-04-15
FI855130A (fi) 1986-06-22
JPH07213292A (ja) 1995-08-15
AU5510490A (en) 1990-10-25
PT81754B (pt) 1987-12-30
FI86194B (fi) 1992-04-15
PT81754A (en) 1986-01-02
EP0368367A1 (fr) 1990-05-16
DK399786D0 (da) 1986-08-21
IE58709B1 (en) 1993-11-03
EP0216786B1 (fr) 1992-03-18
DE3585690D1 (de) 1992-04-23
FI86194C (fi) 1992-07-27
KR940010865B1 (ko) 1994-11-18
ES550260A0 (es) 1987-05-01
EP0313104A2 (fr) 1989-04-26
JP2548526B2 (ja) 1996-10-30
NZ214711A (en) 1991-11-26

Similar Documents

Publication Publication Date Title
WO1986003751A3 (fr) Purification, production et utilisation de facteurs necrotiques tumoraux
FI943750A (fi) Menetelmä nekroositekijän valmistamiseksi
ES8403969A1 (es) Un metodo para producir polipetido semejante a interferon inmune humano.
DE10399023I1 (de) TFN-bindende Proteine
HUT43627A (en) Dns sequences, recombinant dns molekules, and process for producing mis-like polypeptides
ATE380866T1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors,deren herstellung und verwendungen
EP0315683A4 (fr) Sequences adn, molecules adn recombinant, et procedes de production de l'antigene-3 associe a la fonction lymphocyte.
EP0662137B8 (fr) Procedes et compositions de transcription genique et de rayonnement ionisant
ES8601237A1 (es) Procedimiento para preparar dnas y dnas recombinantes
EA002688B1 (ru) Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов
IL92257A0 (en) Binding proteins for insulin-like growth factors,pharmaceutical compositions containing them and dna fragments encoding them
EP0091527A3 (fr) Séquences d'ADN, molécules d'ADN recombinant et procédé de préparation de polypeptides du genre de sérumalbumine humaine
NZ212937A (en) Omega interferons: production by recombinant dna processes; pharmaceutical compositions
AU7154901A (en) Replication deficient adenoviral tnf vector
WO2022009123A4 (fr) Variants d'il-2
CA2128215A1 (fr) L'autotaxine, proteine stimulant la motilite qui est utile dans le diagnostic et le traitement du cancer
AU6259586A (en) Novel plasmid containing TNF gene and use thereof
JPS57200400A (en) Desamidosecretin gene and plasmid
ES8800984A1 (es) Un metodo para obtener adn que codifica factor de necrosis de tumores mutante

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986900138

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWP Wipo information: published in national office

Ref document number: 1986900138

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1986900138

Country of ref document: EP